Dashboard
Manage Tickers

GMABGENMAB A/S

Nasdaq genmab.com


$ 30.28 $ 0.52 (1.75 %)    

Wednesday, 15-May-2024 11:32:15 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 450.50 $ 1.58 (0.35 %)
DIA $ 398.46 $ 2.88 (0.73 %)
SPY $ 528.07 $ 2.11 (0.4 %)
TLT $ 91.95 $ 0.11 (0.12 %)
GLD $ 220.62 $ 1.38 (0.63 %)
$ 29.53
$ 29.76
$ 30.25 x 100
$ 0.00 x 0
$ 29.75 - $ 30.28
$ 26.32 - $ 42.72
652,226
na
132.89M
$ 0.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

genmab-announces-presentation-of-multiple-abstracts-on-epcoritamab-at-2024-european-hematology-association-congress-on-june-13-16
Genmab Announces Presentation Of Multiple ...
05/14/2024 14:10:14

genmab-announces-presentation-of-multiple-abstracts-on-epcoritamab-at-2024-european-hematology-association-congress-on-june-13-16-2024
Genmab Announces Presentation Of Multiple ...
05/14/2024 14:09:41

Core News & Articles
Watching Genmab; Shares Trading Higher Aft...
05/13/2024 16:00:50

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
05/03/2024 19:59:17

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

genmab-q1-2024-revenue-60425m
Genmab Q1 2024 Revenue $604.25M
05/02/2024 15:05:48

decoding-9-analyst-evaluations-for-genmab
Decoding 9 Analyst Evaluations For Genmab
04/30/2024 12:00:57

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
04/30/2024 10:22:57

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

Core News & Articles
FDA OKs Seagen's Tivdak (tisotumab vedotin...
04/29/2024 19:53:09

- Bloomberg

genmab-reports-darzalex-q1-net-sales-of-2692b
Genmab Reports DARZALEX Q1 Net Sales Of $2...
04/16/2024 10:42:24

profoundbio-discovers-the-joys-of-having-a-wealthy-owner
ProfoundBio Discovers The Joys Of Having A...
04/08/2024 15:43:57

Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The d...

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
04/04/2024 15:26:23

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

genmab-to-acquire-profoundbio-for-18b-cash-enhancing-and-expanding-its-oncology-portfolio
Genmab To Acquire ProfoundBio For $1.8B Ca...
04/03/2024 05:42:07

Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in...

hc-wainwright--co-maintains-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Maintains Buy on Genma...
03/27/2024 10:29:18

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

morgan-stanley-maintains-underweight-on-genmab-maintains-32-price-target
Morgan Stanley Maintains Underweight on Ge...
03/26/2024 15:03:49

Morgan Stanley analyst Matthew Harrison maintains Genmab (NASDAQ:GMAB) with a Underweight and maintains $32 price target.

analyst-ratings-for-genmab
Analyst Ratings For Genmab
03/26/2024 14:00:35

truist-securities-maintains-buy-on-genmab-maintains-50-price-target
Truist Securities Maintains Buy on Genmab,...
03/26/2024 13:29:43

Truist Securities analyst Asthika Goonewardene maintains Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

genmab-announces-initiation-dkk35b-share-buy-back-program
Genmab Announces Initiation DKK3.5B Share ...
03/15/2024 12:19:25

hc-wainwright--co-reiterates-buy-on-genmab-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Genm...
03/06/2024 13:04:26

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab (NASDAQ:GMAB) with a Buy and maintains $50 price target.

Core News & Articles
Genmab And AbbVie Announced FDA Granted Pr...
02/27/2024 12:47:06

4-analysts-assess-genmab-what-you-need-to-know
4 Analysts Assess Genmab: What You Need To...
02/20/2024 15:00:28

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION